Factor 11a Inhibitors vs DOACs: The New Standard in Anticoagulation Therapy? Introduction Venous thromboembolism (VTE) affects nearly 900,000 people annually in the United States, with an estimated 60,000-100,000 individuals dying from related complications. Factor 11a inhibitors represent a promising new frontier in anticoagulation
Tag: osocimab
